UPDATE: Mizuho Reiterates Buy On Concert Pharmaceuticals, Raises Target To $29 As Firm Notes Co's 'Strong Data from CTP-543 12mg Dose'; Firm Raises 'probability of success for CTP-543 from 35% to 60%'